Fetal hemoglobin induction with butyric acid: efficacy and toxicity.
Butyric acid induces fetal hemoglobin (HbF), a property of potential therapeutic advantage in patients with disorders of globin chain synthesis. We performed dose escalation studies of this compound in baboons to assess whether clinically significant increases in HbF are achievable, and to define the associated toxicities. Additionally, the effect of butyrate in combination with erythropoietin on HbF induction was assessed. HbF induction in response to butyrate was dependent on the dose and duration of treatment. Doses of butyrate less than 4 g/kg/d were associated with minimal toxicity (hypokalemia) and significant HbF induction in these nonanemic animals, with 1 g/kg/d producing an increase in HbF-containing reticulocytes (F reticulocytes) from 0.9% to 8.7% and an increase in HbF from 0.8% to 1.4%. A dose of 2 g/kg/d resulted in an increase in F reticulocytes from 2.1% to 27.8% and an increase in HbF from 0.7% to 2.2%. Doses of 4 g/kg/d in another animal produced an increase in F reticulocytes from 1% to 21.6% and in HbF from 1.9% to 5.3%. Infusions in excess of 4 g/kg/d were complicated (after a variable amount of time) by a decreased level of alertness (caused by hyperosmolality or butyrate itself) and hematologic toxicity (with declines in reticulocyte, white blood cell, and platelet counts). Prolonged infusions of high doses of butyrate (8 to 10 g/kg/d) were associated with peak F reticulocyte percentages reaching 38% to 64.5% and HbF reaching levels in excess of 20%. These high doses (8 to 10 g/kg/d) were complicated in two animals with a striking and unique neuropathologic picture and, in one animal, multiorgan system failure. Erythropoietin in combination with butyrate, induced F reticulocytosis in an additive manner. We conclude that butyric acid is a strong inducer of HbF, particularly when administered in combination with erythropoietin. As chronic toxicities remain undefined, patients in future clinical trials of this and similar compounds should be monitored closely for evidence of neurologic toxicity.
Blau
C A
CA
Division of Medical Oncology, University of Washington, Seattle.
Constantoulakis
P
P
Shaw
C M
CM
Stamatoyannopoulos
G
G
D000818:Animals; D002087:Butyrates / Q000494:pharmacology* / Q000633:toxicity; D020148:Butyric Acid; D002531:Cerebellum / Q000187:drug effects / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D004906:Erythrocyte Count / Q000187:drug effects; D004921:Erythropoietin / Q000494:pharmacology*; D006400:Hematocrit; D006451:Hemoglobin, Sickle / Q000096:biosynthesis*; D007700:Kinetics; D007958:Leukocyte Count / Q000187:drug effects; D008526:Medulla Oblongata / Q000187:drug effects / Q000473:pathology*; D009336:Necrosis; D010215:Papio; D010976:Platelet Count / Q000187:drug effects; D012156:Reticulocytes / Q000187:drug effects; D013997:Time Factors
D002087:Butyrates; D006451:Hemoglobin, Sickle; D020148:Butyric Acid; D004921:Erythropoietin